Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.61 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 6/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16743005 | 1.00 | CRBN (0.61) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL21333906 | 0.97 | CRBN (0.60) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL29986584 | 0.97 | CRBN (0.60) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL30438173 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL22464272 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL30437678 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL22464729 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL30438170 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL30438172 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 | |
| SCHEMBL30189515 | 0.96 | CRBN (0.59) | CRBNMAP1LC3BIKZF3IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | claimed |
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| CN-115611902-B | Protein degradation compound designed based on Bruton tyrosine kinase ligand and application thereof | 标新生物医药科技(上海)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4426700-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-113365699-B | Target ubiquitin degradation BRD4 protein compound, and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-112079866-B | ALK protein regulator and anti-tumor application thereof | 上海科技大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| EP-4288416-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-111205282-B | ER protein modulators and uses thereof | 上海科技大学 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081452-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | disclosed |
| WO-2023030170-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023284703-A1 | PROTEIN DEGRADATION COMPOUND DESIGNED ON THE BASIS OF BRUTON'S TYROSINE KINASE LIGAND AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611902-A | Protein degradation compound designed based on Bruton's tyrosine kinase ligand and application thereof | 标新生物医药科技(上海)有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022169834-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | CRBN 510/4885MAP1LC3B 1285/4885IKZF3 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.